The Regulatory Mechanism of Hypoxia-inducible Factor 1 and its Clinical Significance

被引:2
|
作者
Yin, Chun-Li [1 ,2 ]
Ma, Yu-Jie [1 ,2 ]
机构
[1] Anhui Med Univ, AF Clin Coll, Clin Coll 5, Hefei 230032, Peoples R China
[2] PLA AF Med Ctr, Dept Crit Care Med, 30 Fucheng Rd, Beijing 100142, Peoples R China
关键词
Hypoxia; Hypoxia-inducible factor 1; Hypoxia-inducible factor pathway; Isoforms; Diseases; Amino acid; FACTOR-I; FACTOR (HIF)-1-ALPHA; PROLYL HYDROXYLASES; CANCER CELLS; MAP KINASE; HIF-ALPHA; EXPRESSION; HIF-1-ALPHA; GROWTH; DEGRADATION;
D O I
10.2174/0118761429266116231123160809
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hypoxia-inducible factor (HIF) is a nuclear protein that plays a crucial role in oxygen homeostasis through its transcriptional activity and thousands of target gene profiles. Through transcriptional and post-transcriptional regulation, the downstream target genes of HIF can trigger multiple pathological responses in the body, including energy metabolism, cytopenia, and angiogenesis. There are three distinct subtypes of HIF: HIF-1, HIF-2, and HIF-3. HIF-1 is a significant regulator of the cellular response to hypoxia, and the balance between its production and degradation is critical for this response. As hypoxia is linked to several disorders, understanding HIF can open up novel avenues for the treatment of many diseases. This review describes the regulatory mechanisms of HIF-1 synthesis and degradation and the clinical significance of the hypoxia-inducible factor pathway in lung injury, kidney disease, hematologic disorders, and inflammation-related diseases.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Clinical significance of hypoxia-inducible factor 1 and VEGF-A in osteosarcoma
    Huanli Zhao
    Yuhui Wu
    Yang Chen
    Hongmei Liu
    [J]. International Journal of Clinical Oncology, 2015, 20 : 1233 - 1243
  • [2] Clinical significance of hypoxia-inducible factor 1 and VEGF-A in osteosarcoma
    Zhao, Huanli
    Wu, Yuhui
    Chen, Yang
    Liu, Hongmei
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (06) : 1233 - 1243
  • [3] Hypoxia-inducible factor 1α expression and its clinical significance in pancreatic cancer: A meta-analysis
    Ye, Long-Yun
    Zhang, Qi
    Bai, Xue-Li
    Pankaj, Prasoon
    Hu, Qi-Da
    Liang, Ting-Bo
    [J]. PANCREATOLOGY, 2014, 14 (05) : 391 - 397
  • [4] Hypoxia-inducible factor 1α or hypoxia-inducible factor 2α is not required for the development and physiological function of regulatory T cells
    Lai, Ming-Zong
    Hsu, Tzu-Sheng
    Lin, Yen-Lin
    Hsieh, Wan-Chen
    [J]. CYTOKINE, 2017, 100 : 158 - 158
  • [5] Expression of hypoxia-inducible factor 1α in gastric cancer and its clinical signficance
    吴友亮
    [J]. China Medical Abstracts (Internal Medicine), 2016, 33 (03) : 168 - 168
  • [6] Expression significance and potential mechanism of hypoxia-inducible factor 1 alpha in patients with myelodysplastic syndromes
    Liang, Hai-wei
    Luo, Bin
    Du, Li-hua
    He, Rong-quan
    Chen, Gang
    Peng, Zhi-gang
    Ma, Jie
    [J]. CANCER MEDICINE, 2019, 8 (13): : 6021 - 6035
  • [7] The clinical significance and regulation mechanism of hypoxia-inducible factor-1 and miR-191 expression in pancreatic cancer
    Song, Zhenguo
    Ren, He
    Gao, Song
    Zhao, Xiao
    Zhang, Huan
    Hao, Jihui
    [J]. TUMOR BIOLOGY, 2014, 35 (11) : 11319 - 11328
  • [8] Clinicopathologic significance of hypoxia-inducible factor 1α overexpression in gastric carcinomas
    Mizokami, Ken
    Kakeji, Yoshihiro
    Oda, Shinya
    Irie, Koji
    Yonemura, Tomohiro
    Konish, Fumio
    Maehara, Yoshihiko
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2006, 94 (02) : 149 - 154
  • [9] Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia
    Kizaka-Kondoh, Shinae
    Konse-Nagasawa, Hideko
    [J]. CANCER SCIENCE, 2009, 100 (08): : 1366 - 1373
  • [10] Hypoxia-inducible factor 1.
    Zhang, JF
    Chen, GH
    Tang, J
    [J]. PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 1998, 25 (02) : 101 - 103